Reiter E.O.,Tufts University |
Mauras N.,Nemours Childrens Clinic |
McCormick K.,University of Alabama at Birmingham |
Kulshreshtha B.,All India Institute of Medical Sciences |
And 5 more authors.
Journal of Pediatric Endocrinology and Metabolism | Year: 2010
Objective: To evaluate the efficacy, tolerability, and pharmacokinetics of bicalutamide plus anastrozole in young males with testotoxicosis. Methods: This was a multicenter, open-label, single-arm, 12-month, Phase II pilot trial in 14 males (2-9 years) with testotoxicosis treated with bicalutamide (12.5, 25, 50, or 100 mg) and anastrozole (0.5 or 1 mg) daily. The primary outcome was change in growth rate. Results: At 1 year, the mean (standard deviation) change from baseline in growth rate was -1.6 (± 5.1) cm/year and -0.1 (± 1.8) SD units, and in bone maturation was -2.3 (± 0.5) years. The bone age/chronological age ratio was reduced from 2.1 (± 0.6) at baseline to 1.0 (± 0.4) (p = 0.00013). Steady-state trough Rbicalutamide and anastrozole concentrations were attained by Day 21 and 8, respectively. Gynecomastia (42.9%) and breast tenderness (12.5%) were the most common treatmentrelated adverse events. Conclusions: Treatment of testotoxicosis with bicalutamide plus anastrozole resulted in slower growth rate. © Freund Publishing House Ltd., London. Source